{
  "docId": "019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "docSlug": "78e7004510e3b27003e9c94a6172e682",
  "documentTitle": "Chimerix | Investor Presentation Deck | 38 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 38,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-80bf-72b8-b7b1-d0f771f9e60f/3",
  "deckHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f",
  "deckJsonHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f.json",
  "deckAnchorHref": "/decks/019de074-80bf-72b8-b7b1-d0f771f9e60f#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.8,
        "w": 0.31,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "list",
      "text": "High probability of success for Phase 3 ACTION study of ONC201; Phase 2 study designed to isolate single agent activity; Durable responses; Independent disease history studies; Genetically selected patient population.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1d624207-2ad7-493c-a5d2-ba296496bbbe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.31,
        "x": 0.67,
        "y": 0.13
      },
      "kind": "list",
      "text": "Corporate capability and financial flexibility; Leadership team track record; Strong balance sheet; Non-dilutive TEMBEXA milestones; Track record of objectivity.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2498070d-c5cb-4e49-8437-d681de889045",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.8,
        "w": 0.31,
        "x": 0.35,
        "y": 0.13
      },
      "kind": "list",
      "text": "Low barriers to commercial potential for ONC201; Terminal disease with no effective options; High awareness; U.S. patent exclusivity through 2037; Global revenue potential of ~$750m.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8cd74ca-5234-44bb-b117-8321eeba7b74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.32,
        "x": 0.34,
        "y": 0.04
      },
      "kind": "title",
      "text": "Investment highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37be1a38-bcf7-4d1a-9e37-b26250fa0371",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "05b21c2e-96e7-42bd-a5c3-7e06a1f24abe",
      "evidence": "list/bullet: High probability of success for Phase 3 ACTION study of ONC201",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}